期刊文献+

T1~2期人表皮生长因子受体2阳性型及非阳性型浸润性乳腺癌微钙化特点比较 被引量:3

Comparison of characteristics of microcalcification in patients with T1~2 stage HER2 positive and non-positive invasive breast cancer
下载PDF
导出
摘要 目的 分析T1~2期人表皮生长因子受体2(HER2)阳性型及非阳性型浸润性乳腺癌(IBC)病人微钙化(MC)的特点。方法 T1~2期IBC病人254例,采用乳腺X线诊断系统评估MC形态,分析HER2阳性型及非阳性型者MC发生及特点。结果 MC发生率为53.54%(136/254),HER2阳性型MC的发生率高于非阳性型(79.37%vs 45.03%,P<0.05);HER2阳性型MC以沿导管分布的细线分支样多见,非阳性型以簇状分布针尖样多见,两组间的MC形态及分布比较差异有统计学意义(P<0.05);HER2阳性组中,50岁以上病人MC发生率高于50岁及以下者,差异有统计学意义(P<0.05)。结论 HER2阳性型IBC病人MC发生率更高,MC的形态及分布对HER2表达状态预测有一定指导意义。 Objective To analyze the characteristics of breast microcalcification(MC) in patients with T1~2 stage human epidermal growth factor receptor 2(HER2) positive and non-positive invasive breast cancer(IBC).Methods Retrospectively analyzed the clinicopathological data of 254 patients with T1~2 stage IBC.To analyze the occurrence and characteristics of MC in HER2 positive and non-positive patients.Results In this study, the incidence of MC was 53.54%(136/254),The incidence of MC in the HER2 positive group was higher than that in the non-positive group(79.37%vs 45.03%,P<0.05).In HER2 positive group, MC was mainly branching samples of thin lines distributed along ducts, while in non-positive group, it was more common to have needle tip like cluster distribution.There were significant differences in MC morphology and distribution between the two groups(P<0.05).In HER2 positive patients, the incidence of MC in patients who was older than 50 years was higher than that in patients who was 50 years and younger(P<0.05).Conclusion The incidence of MC was higher in HER2-positive IBC patients, and the morphology and distribution of MC had certain guiding significance in predicting the expression status of HER2.
作者 马强 杨丽 何建信 张春霞 郝金燕 MA Qiang;YANG Li;HE Jianxin(Department of General Surgery,Beijing Shunyi Hospital,Beijing 101300,China)
出处 《临床外科杂志》 2022年第2期156-159,共4页 Journal of Clinical Surgery
关键词 浸润性乳腺癌 人表皮生长因子受体2 微钙化 invasive breast carcinoma human epidermal growth factor receptor-2 microcalcification
  • 相关文献

参考文献9

二级参考文献39

  • 1张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3Viale G,Regan MM,Maiorano E,et al.Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:BIG 1-98[J].J Clin Oncol,2007,25(25):3846-3852.
  • 4Rhodes A,Jasani B,Balaton AJ,et al.Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas:Correlation with patient age,assay sensitivity,threshold value,and mammographic screening[J].J Clin Pathol,2000,53(9):688-696.
  • 5Zhang Z,Wang J,Skinner KA,et al.Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression[J].Histopathology,2014,65(4):508-516.
  • 6Harvey JM,Clark GM,Osbome CK,et al.Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer[J].J Clin Oncol,1999,17(5):1474-1481.
  • 7Elledge RM,Green S,Pugh R,et al.Estrogen receptor(ER)and progesterone receptor(PgR),by ligand-binding assay compared with ER,PgR and pS2,by immunohistocheniistiy in predicting response to tamoxifen in metastatic breast cancer:A Southwest Oncology Group study[J].Int J Cancer,2000,89?2):111-117.
  • 8Hammond ME,Hayes DF,Dowsett M,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J].J Clin Oncol,2010,28(16):2784-2795.
  • 9Wolff AC,Hammond ME,Schwartz JN,et al.American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].J Clin Oncol,2007,25(1):118-145.
  • 10Goldhirsch A,Winer EP,Coates AS,et al.Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013[J].Ann Oncol,2013,24(9);2206-2223.

共引文献444

同被引文献43

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部